DOCSLIB.ORG

Immunotherapy in the Prevention and Treatment of Chronic Fungal Infections

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immunotherapy in the Prevention and Treatment of Chronic Fungal Infections A chance for treatment - immunotherapy in the prevention and treatment of chronic fungal infections Frank L. van de Veerdonk Radboud Center for Infectious diseases (RCI) ESCMID eLibrary © by author Candida infections Mucocutaneous infections Invasive candidiasis Th ESCMIDT helper cells eLibraryPhagocytes © by author Chronic Candida infection 30% to 50% of individuals are colonized with Candida at any given moment, but only rarely causing mucosal infections Even more rarely are these infections chronic However, several clinical syndromes have been described with chronic CandidaESCMIDinfections eLibrary © by author Mucosal host defence against Candida ESCMID eLibrary Nature Microbiol. Reviews 2012 © by author Mucosal host defence against Candida ESCMID eLibrary Nature Microbiol. Reviews 2012 © by author Chronic Candida infections Hyper IgE syndrome (HIES) Dectin-1/CARD9 deficiency Chronic mucocutaneous candidiasis (STAT1 GOF, APECED, IL-17F, IL-17R) ESCMID eLibrary © by author Characteristics of Hyper IgE syndrome ESCMID eLibrary © by author Loss of function STAT3 mutation Heterozygous mutation in STAT3 ESCMIDDominant negative eLibrary © by author Cytokine signalling INTERLEUKIN-6/23 IL-6/IL-23 RECEPTOR STAT3 phosphorylation IL-17 ESCMID eLibrary PMN Levy and Loomis et al, NEJM 2007 © by author Th17 deficiency in HIES IL-17 ESCMID eLibrary IFNg van de Veerdonk et al, Clin Exp Immunol© 2010by author Chronic Candida infections Hyper IgE syndrome (HIES) Dectin-1/CARD9 deficiency Chronic mucocutaneous candidiasis ESCMID eLibrary © by author Dectin-1/CARD9 recognition pathway Candida Cell wall Mannans ESCMIDb-glucans eLibrary © by author Dectin-1 deficiency - Recurrent vulvovaginal infections - Onychomycosis ESCMID eLibrary Ferwerda et al. NEJM 2009 © by author Decreased Th17 response ESCMID eLibrary © by author Dectin-1 deficiency dectin-1 con Loss of a Glutamic acid that binds calcium dectin-1 pat Folding/transport is disturbed no expression of dectin-1 at ESCMID eLibrarythe cell membrane © by author CARD9 deficiency - Increased susceptibility to both mucocutaneous and systemic Candida infections (brain) - Deficient Th17 response ESCMID eLibrary Glocker et al. NEJM 2009 © by author CLR-CARD9 pathway ESCMID eLibrary © by author Chronic Candida infections Hyper IgE syndrome (HIES) Dectin-1/CARD9 deficiency Chronic mucocutaneous candidiasis ESCMID eLibrary © by author APECED AIRE gene: autoimmune regulator on chr. 21 Expression in thymus: ESCMID eLibraryimportant for depletion of autoreactive cells Nature Genetics 1997 © by author Auto-antibodies against IL-17 ESCMID eLibrary © by author Th17 deficiency: How important is IL-17 for controlling mucosal candidiasis? ESCMID eLibrary © by author ESCMID eLibrary Autosomal recessive IL-17RA deficiency Autosomal dominant IL-17F deficiency © by author IL-17 signalling pathway ESCMID eLibrary © by author IL-17 signalling pathway ESCMID eLibrary © by author Family with autosomal dominant CMC ESCMID eLibrary van de Veerdonk et al, NEJM 2011 © by author Chronic mucocutaneous candidiasis (CMC) ESCMID CharleseLibrary Kirkpatrick © by author First documented CMC? ESCMID eLibrary Ferdinand Bol, Vier regenten van het© Leprozenhuis, 1649by author First documented CMC? ESCMID eLibrary Ferdinand Bol, Vier regenten van het© Leprozenhuis, 1649by author T helper cytokines ESCMID eLibrary © by author Systematical approach Neutrophil Interleukin(IL) ESCMID-1 eLibrary TNF © by author Th1: defective IL-12 response IL-12 Th1 ESCMID eLibraryIFN g © by author Th17: defective IL-23 response IL-23 Th17 IL-17 ESCMID eLibraryIL-22 Van de Veerdonk et al, NEJM 2011 © by author Molecules shared by IL-12 and IL-23 pathways Upstream Downstream ESCMID eLibrary © by author Next generation sequencing All exons from 100 selected genes Mutation in STAT1 ESCMID eLibraryArg274Trp © by author Many more STAT1 mutations ESCMID eLibrary © by author What is the mechanism leading to susceptibility to mucocutaneous candidiasis? ESCMID eLibrary © by author STAT molecules INTERLEUKINS RECEPTOR STAT phosphorylation IL-17 ESCMID eLibrary Levy and Loomis, NEJM 2007 © by author STAT1 hyperphosphorylation ESCMID eLibrary © by author Gain of function mutation STAT1 hyperphosphorylation ESCMID eLibrary Liu et al., JEM 2011 © by author Hypothesis Hypothesis Th17 responses IFN type I and II IL-27 STAT1 GOF ESCMID eLibrary © by author Immunomodulatory options? ESCMID eLibrary © by author Hypothesis IL-23 Th17 STAT3 IL-17 ESCMID eLibrary © by author Hypothesis IL-23 STAT1 GOF Th17 STAT3 IL-17 ESCMID eLibrary © by author HypothesisSTAT1 inhibitor (fludarabine) IL-23 STAT1 GOF Th17 STAT3 IL-17 ESCMID eLibrary © by author HypothesisSTAT1 inhibitor (fludarabine) IL-23 STAT1 GOF Th17 STAT3 IL-17 IL-22 ESCMID eLibrary © by author STAT1 GOF clinical phenotype - Chronic candida/trichophyton infection skin and mucosa (long known) - Severe disseminated cutaneous fusariosis - Disseminated endemic mycosis (Coccidioidomycosis and histoplasmosis) - Disseminated aspergillosis - Viral infections (herpes) - IPEX like syndrome - PD-L1 overexpression and decreased B cell survival - Progression to full SCID - Cerebral and pulmonary arterial aneurysms - Esophageal and oropharyngeal carcinomas - ESCMIDAutoimmune diseases (AHIA, autoimmune eLibrary hepatitis) © by author Hypothesis Hypothesis Th17 responses IFN type I and II IL-27 STAT1 GOF ? ESCMIDWhat else….. eLibrary © by author Trained immunity training (H3K4me3) e s n priming Quintin et al., CHM, 2012 o p s e r e n u homeostasis m m i tolerance (H3K4me3) e t a Foster et al., Nature 2007 n n i duration (days/weeks?) primary secondary infESCMIDection infection eLibrary Saeed, Quintin et al, Science, 2014 © by author Hypothesis b-glucan-induced Trained immunity ESCMID eLibrary © by author Epigenetic modification by STAT1? ESCMID eLibrary © by author Epigenetic modification by STAT1? ESCMID eLibrary © by author Epigenetic modification by STAT1? IL-23 Th17 STAT1 GOF STAT3 IL-17 ILESCMID-22 eLibrary © by author Hypothesis Another approach Th17 responses IFN type I and II IL-27 STAT1 GOF ESCMID eLibrary © by author Ruxolitinib (JAK1/JAK2 inhibitor) ESCMID eLibrary © by author ESCMID eLibrary © by author Ruxolitinib STAT1 ESCMID eLibrary © by author Ruxolitinib STAT1 ESCMID eLibrary © by author Take home messages Dysregulated Th17 responses play a major role in chronic Candida infections Restoring dysregulated STAT1-STAT3 activation in CMC: - Direct inhibition of STAT1 - Epigenetic modulation - Indirect via JAK inhibitors or anti-cytokine antibodies Future:ESCMID gene surgery? eLibrary © by author University of Colorado Mark Gresnigt Tania Azam Katharina Becker Charles Dinarello Berenice Rosler Xiaowen Wang East Tennessee State University James Cheng David Williams Ralph Maas Sanne Smeekens Newcastle University UK Bart Ferwerda Desa Lilic Marije Oosting Gerben Ferwerda NIH Liesbeth Jacobs Ofer Zimmerman Alexander Hoischen Steven Holland Joris Veltman Jos van der Meer INSERM Leo Joosten Anne Puel Bart Jan Kullberg Mihai Netea Freiburg University ESCMIDBodo Grimbacher eLibrary © by author ESCMID eLibrary © by author.
Load more

Recommended publications
  • An Overview of the Management of the Most Important Invasive Fungal Infections in Patients with Blood Malignancies
    Infection and Drug Resistance Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW An Overview of the Management of the Most Important Invasive Fungal Infections in Patients with Blood Malignancies This article was published in the following Dove Press journal: Infection and Drug Resistance Aref Shariati 1 Abstract: In patients with hematologic malignancies due to immune system disorders, espe- Alireza Moradabadi2 cially persistent febrile neutropenia, invasive fungal infections (IFI) occur with high mortality. Zahra Chegini3 Aspergillosis, candidiasis, fusariosis, mucormycosis, cryptococcosis and trichosporonosis are Amin Khoshbayan 4 the most important infections reported in patients with hematologic malignancies that undergo Mojtaba Didehdar2 hematopoietic stem cell transplantation. These infections are caused by opportunistic fungal pathogens that do not cause severe issues in healthy individuals, but in patients with hematologic 1 Department of Microbiology, School of malignancies lead to disseminated infection with different clinical manifestations. Prophylaxis Medicine, Shahid Beheshti University of fi Medical Sciences, Tehran, Iran; and creating a safe environment with proper lters and air pressure for patients to avoid contact 2Department of Medical Parasitology and with the pathogens in the surrounding environment can prevent IFI. Furthermore, due to the Mycology, Arak University of Medical fi For personal use only. absence of speci c symptoms in IFI, rapid and accurate diagnosis reduces
    [Show full text]
  • Oral Candidiasis: a Review
    International Journal of Pharmacy and Pharmaceutical Sciences ISSN- 0975-1491 Vol 2, Issue 4, 2010 Review Article ORAL CANDIDIASIS: A REVIEW YUVRAJ SINGH DANGI1, MURARI LAL SONI1, KAMTA PRASAD NAMDEO1 Institute of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur (C.G.) – 49500 Email: [email protected] Received: 13 Jun 2010, Revised and Accepted: 16 July 2010 ABSTRACT Candidiasis, a common opportunistic fungal infection of the oral cavity, may be a cause of discomfort in dental patients. The article reviews common clinical types of candidiasis, its diagnosis current treatment modalities with emphasis on the role of prevention of recurrence in the susceptible dental patient. The dental hygienist can play an important role in education of patients to prevent recurrence. The frequency of invasive fungal infections (IFIs) has increased over the last decade with the rise in at‐risk populations of patients. The morbidity and mortality of IFIs are high and management of these conditions is a great challenge. With the widespread adoption of antifungal prophylaxis, the epidemiology of invasive fungal pathogens has changed. Non‐albicans Candida, non‐fumigatus Aspergillus and moulds other than Aspergillus have become increasingly recognised causes of invasive diseases. These emerging fungi are characterised by resistance or lower susceptibility to standard antifungal agents. Oral candidiasis is a common fungal infection in patients with an impaired immune system, such as those undergoing chemotherapy for cancer and patients with AIDS. It has a high morbidity amongst the latter group with approximately 85% of patients being infected at some point during the course of their illness. A major predisposing factor in HIV‐infected patients is a decreased CD4 T‐cell count.
    [Show full text]
  • Epidemiology of Invasive Fungal Diseases in Patients With
    Journal of Fungi Article Epidemiology of Invasive Fungal Diseases in Patients with Hematologic Malignancies and Hematopoietic Cell Transplantation Recipients Managed with an Antifungal Diagnostic Driven Approach Maria Daniela Bergamasco 1 , Carlos Alberto P. Pereira 1, Celso Arrais-Rodrigues 2, Diogo B. Ferreira 1 , Otavio Baiocchi 2, Fabio Kerbauy 2, Marcio Nucci 3 and Arnaldo Lopes Colombo 1,* 1 Division of Infectious Diseases, Hospital São Paulo-University Hospital, Universidade Federal de São Paulo, São Paulo 04024-002, Brazil; [email protected] (M.D.B.); [email protected] (C.A.P.P.); [email protected] (D.B.F.) 2 Division of Hematology, Hospital São Paulo-University Hospital, Universidade Federal de São Paulo, São Paulo 04024-002, Brazil; [email protected] (C.A.-R.); [email protected] (O.B.); [email protected] (F.K.) 3 Department of Internal Medicine, Hospital Universitário Clementino Frafa Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-913, Brazil; [email protected] * Correspondence: [email protected] or [email protected] Abstract: Patients with hematologic malignancies and hematopoietic cell transplant recipients (HCT) Citation: Bergamasco, M.D.; Pereira, are at high risk for invasive fungal disease (IFD). The practice of antifungal prophylaxis with mold- C.A.P.; Arrais-Rodrigues, C.; Ferreira, active azoles has been challenged recently because of drug–drug interactions with novel targeted D.B.; Baiocchi, O.; Kerbauy, F.; Nucci, therapies. This is a retrospective, single-center cohort study of consecutive cases of proven or probable M.; Colombo, A.L. Epidemiology of IFD, diagnosed between 2009 and 2019, in adult hematologic patients and HCT recipients managed Invasive Fungal Diseases in Patients with fluconazole prophylaxis and an antifungal diagnostic-driven approach for mold infection.
    [Show full text]
  • Prostatic Cryptococcosis - a Case Report
    Received: November 8, 2007 J. Venom. Anim. Toxins incl. Trop. Dis. Accepted: April 1, 2008 V.14, n.2, p.378-385, 2008. Abstract published online: April 2, 2008 Case report. Full paper published online: May 31, 2008 ISSN 1678-9199. PROSTATIC CRYPTOCOCCOSIS - A CASE REPORT CHANG M. R. (1), PANIAGO A. M. M. (2), SILVA M. M. (3), LAZÉRA M. S. (4), WANKE B. (4) (1) Department of Pharmacy-Biochemistry, Federal University of Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul State, Brazil; (2) Department of Internal Medicine, UFMS, Campo Grande, Mato Grosso do Sul State, Brazil; (3) Medicine Program, University for Development of the State and the Pantanal Region (UNIDERP), Campo Grande, Mato Grosso do Sul State, Brazil; (4) Mycology Service Evandro Chagas Institute of Clinical Research (IPEC), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Rio de Janeiro State, Brazil. ABSTRACT: Cryptococcosis is a systemic mycosis usually affecting immunodeficient individuals. In contrast, immunologically competent patients are rarely affected. Dissemination of cryptococcosis usually involves the central nervous system, manifesting as meningitis or meningoencephalitis. Prostatic lesions are not commonly found. A case of prostate cryptococcal infection is presented and cases of prostatic cryptococcosis in normal and immunocompromised hosts are reviewed. A fifty-year-old HIV-negative man with urinary retention and renal insufficiency underwent prostatectomy due to massive enlargement of the organ. Prostate histopathologic examination revealed encapsulated yeast-like structures. After 30 days, the patient’s clinical manifestations worsened, with headache, neck stiffness, bradypsychia, vomiting and fever. Direct microscopy of the patient’s urine with China ink preparations showed capsulated yeasts, and positive culture yielded Cryptococcus neoformans.
    [Show full text]
  • Application to Add Itraconazole and Voriconazole to the Essential List of Medicines for Treatment of Fungal Diseases – Support Document
    Application to add itraconazole and voriconazole to the essential list of medicines for treatment of fungal diseases – Support document 1 | Page Contents Page number Summary 3 Centre details supporting the application 3 Information supporting the public health relevance and review of 4 benefits References 7 2 | Page 1. Summary statement of the proposal for inclusion, change or deletion As a growing trend of invasive fungal infections has been noticed worldwide, available few antifungal drugs requires to be used optimally. Invasive aspergillosis, systemic candidiasis, chronic pulmonary aspergillosis, fungal rhinosinusitis, allergic bronchopulmonary aspergillosis, phaeohyphomycosis, histoplasmosis, sporotrichosis, chromoblastomycosis, and relapsed cases of dermatophytosis are few important concern of southeast Asian regional area. Considering the high burden of fungal diseases in Asian countries and its associated high morbidity and mortality (often exceeding 50%), we support the application of including major antifungal drugs against filamentous fungi, itraconazole and voriconazole in the list of WHO Essential Medicines (both available in oral formulation). The inclusion of these oral effective antifungal drugs in the essential list of medicines (EML) would help in increased availability of these agents in this part of the world and better prompt management of patients thereby reducing mortality. The widespread availability of these drugs would also stimulate more research to facilitate the development of better combination therapies.
    [Show full text]
  • Identification of Culture-Negative Fungi in Blood and Respiratory Samples
    IDENTIFICATION OF CULTURE-NEGATIVE FUNGI IN BLOOD AND RESPIRATORY SAMPLES Farida P. Sidiq A Dissertation Submitted to the Graduate College of Bowling Green State University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY May 2014 Committee: Scott O. Rogers, Advisor W. Robert Midden Graduate Faculty Representative George Bullerjahn Raymond Larsen Vipaporn Phuntumart © 2014 Farida P. Sidiq All Rights Reserved iii ABSTRACT Scott O. Rogers, Advisor Fungi were identified as early as the 1800’s as potential human pathogens, and have since been shown as being capable of causing disease in both immunocompetent and immunocompromised people. Clinical diagnosis of fungal infections has largely relied upon traditional microbiological culture techniques and examination of positive cultures and histopathological specimens utilizing microscopy. The first has been shown to be highly insensitive and prone to result in frequent false negatives. This is complicated by atypical phenotypes and organisms that are morphologically indistinguishable in tissues. Delays in diagnosis of fungal infections and inaccurate identification of infectious organisms contribute to increased morbidity and mortality in immunocompromised patients who exhibit increased vulnerability to opportunistic infection by normally nonpathogenic fungi. In this study we have retrospectively examined one-hundred culture negative whole blood samples and one-hundred culture negative respiratory samples obtained from the clinical microbiology lab at the University of Michigan Hospital in Ann Arbor, MI. Samples were obtained from randomized, heterogeneous patient populations collected between 2005 and 2006. Specimens were tested utilizing cetyltrimethylammonium bromide (CTAB) DNA extraction and polymerase chain reaction amplification of internal transcribed spacer (ITS) regions of ribosomal DNA utilizing panfungal ITS primers.
    [Show full text]
  • Medicinal Product No Longer Authorised
    European Medicines Agency EMEA/H/C/611 EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) POSACONAZOLE SP EPAR summary for the public This document is a summary of the European Public Assessment Report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, readauthorised the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part of the EPAR). What is Posaconazole SP? Posaconazole SP is an oral suspension that contains the active substance posaconazole (40 mg/ml). What is Posaconazole SP used for? Posaconazole SP is an antifungal medicine. It is used to treatlonger patients with the following diseases, when they cannot tolerate other antifungal medicines (amphotericin B, itraconazole or fluconazole) or have not improved after at least 7 days of treatment with other antifungal medicines: • invasive aspergillosis (a type of fungal infection due to Aspergillus), • fusariosis (another type of fungal infection nodue to Fusarium), • chromoblastomycosis and mycetoma (long-term fungal infections of the skin or the tissue just below the skin, usually caused by fungal spores infecting wounds due to thorns or splinters), • coccidioidomycosis (fungal infection of the lungs caused by breathing in spores). Posaconazole SP is also used to treat patients with oropharyngeal candidiasis or ‘thrush’, a fungal infection of the mouth and throat due to Candida. It is used in patients who have not been treated for this disease before.
    [Show full text]
  • Fungal Foot Infection: the Hidden Enemy?
    Clinical REVIEW Fungal foot infection: the hidden enemy? When discussing tissue viability in the lower limb, much attention is focused on the role of bacterial infection. However, fungal skin infection is a more frequent and more recurrent pathogen which often goes undetected by the practitioner and patient alike. Potentially, untreated fungal foot infection can facilitate secondary problems such as superficial bacterial infections, or, more seriously, lower limb cellulitis. Often simple measures can prevent fungal foot infection and therefore reduce the possibility of complications. This article will review the presentation of tinea pedis and onychomycosis, their effects and management. Ivan Bristow, Manfred Mak Under occlusive and humid conditions increased risk of acquiring the infection. KEY WORDS the fungal hyphae then develop and Patients with diabetes show an increased invade the deeper stratum corneum. susceptibility (Yosipovitch et al, 1998). Fungal Nutrition is afforded by the extra-cellular Boyko et al (2006) have identified the Tinea pedis secretion of proteolytic and keratolytic presence of tinea to be a predictor of Onchomycosis enzymes breaking down the complex foot ulceration in a diabetic population. Cellulitis keratin into simple molecules which can The reason for an increased prevalence be absorbed by the organism (Kaufman in patients with diabetes remains under- et al, 2007). researched. It has been proposed that peripheral neuropathy renders the foot Epidemiology of fungal foot infection insensate reducing individual awareness inea pedis (athlete’s foot) is an Fungal foot infection (FFI) is the most to the presence of infection. Eckhard et inflammatory condition and common infection found on the foot. al (2007) discovered a high prevalence Trepresents the most common of Seldom seen before puberty, the in patients with type 2 diabetes who all the superficial fungal skin infections prevalence rises with age, peaking in the exhibited a lack of sweating when tested (Hay, 1993).
    [Show full text]
  • Allergic Bronchopulmonary Aspergillosis
    Allergic Bronchopulmonary Aspergillosis Karen Patterson1 and Mary E. Strek1 1Department of Medicine, Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, Illinois Allergic bronchopulmonary aspergillosis (ABPA) is a complex clinical type of pulmonary disease that may develop in response to entity that results from an allergic immune response to Aspergillus aspergillus exposure (6) (Table 1). ABPA, one of the many fumigatus, most often occurring in a patient with asthma or cystic forms of aspergillus disease, results from a hyperreactive im- fibrosis. Sensitization to aspergillus in the allergic host leads to mune response to A. fumigatus without tissue invasion. activation of T helper 2 lymphocytes, which play a key role in ABPA occurs almost exclusively in patients with asthma or recruiting eosinophils and other inflammatory mediators. ABPA is CF who have concomitant atopy. The precise incidence of defined by a constellation of clinical, laboratory, and radiographic ABPA in patients with asthma and CF is not known but it is criteria that include active asthma, serum eosinophilia, an elevated not high. Approximately 2% of patients with asthma and 1 to total IgE level, fleeting pulmonary parenchymal opacities, bronchi- 15% of patients with CF develop ABPA (2, 4). Although the ectasis, and evidence for sensitization to Aspergillus fumigatus by incidence of ABPA has been shown to increase in some areas of skin testing. Specific diagnostic criteria exist and have evolved over the world during months when total mold counts are high, the past several decades. Staging can be helpful to distinguish active disease from remission or end-stage bronchiectasis with ABPA occurs year round, and the incidence has not been progressive destruction of lung parenchyma and loss of lung definitively shown to correlate with total ambient aspergillus function.
    [Show full text]
  • Mycosis Fungoides and Sézary Syndrome: an Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy
    cancers Review Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy Nuria García-Díaz 1 , Miguel Ángel Piris 2,† , Pablo Luis Ortiz-Romero 3,† and José Pedro Vaqué 1,*,† 1 Molecular Biology Department, Universidad de Cantabria—Instituto de Investigación Marqués de Valdecilla, IDIVAL, 39011 Santander, Spain; [email protected] 2 Department of Pathology, Fundación Jiménez Díaz, CIBERONC, 28040 Madrid, Spain; [email protected] 3 Department of Dermatology, Hospital 12 de Octubre, Institute i+12, CIBERONC, Medical School, University Complutense, 28041 Madrid, Spain; [email protected] * Correspondence: [email protected] † Same contribution. Simple Summary: In the last few years, the field of cutaneous T-cell lymphomas has experienced major advances. In the context of an active translational and clinical research field, next-generation sequencing data have boosted our understanding of the main molecular mechanisms that govern the biology of these entities, thus enabling the development of novel tools for diagnosis and specific therapy. Here, we focus on mycosis fungoides and Sézary syndrome; we review essential aspects of their pathophysiology, provide a rational mechanistic interpretation of the genomic data, and discuss the current and upcoming therapies, including the potential crosstalk between genomic alterations Citation: García-Díaz, N.; Piris, M.Á.; and the microenvironment, offering opportunities for targeted therapies. Ortiz-Romero, P.L.; Vaqué, J.P. Mycosis Fungoides and Sézary Abstract: Primary cutaneous T-cell lymphomas (CTCLs) constitute a heterogeneous group of diseases Syndrome: An Integrative Review of that affect the skin. Mycosis fungoides (MF) and Sézary syndrome (SS) account for the majority the Pathophysiology, Molecular of these lesions and have recently been the focus of extensive translational research.
    [Show full text]
  • Summary of Risk Management Plan for Posaconazole 40 Mg/Ml Oral Suspension
    Part VI: Summary of the risk management plan Summary of risk management plan for Posaconazole 40 mg/ml oral suspension This is a summary of the risk management plan (RMP) for Posaconazole 40 mg/ml oral suspension. The RMP details important risks of Posaconazole, how these risks can be minimised, and how more information will be obtained about Posaconazole’s risks and uncertainties (missing information). Posaconazole’s summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Posaconazole should be used. I. The medicine and what it is used for Posaconazole is authorised for the treatment of the following fungal infections in adults: invasive aspergillosis, fusariosis, chromoblastomycosis and mycetoma, coccidioidomycosis and oropharyngeal candidiasis. Posaconazole is also indicated for prophylaxis against invasive fungal infections (see SmPC for the full indication). It contains posaconazole as the active substance and it is given as an oral suspension. II. Risks associated with the medicine and activities to minimise or further characterise the risks Important risks of Posaconazole, together with measures to minimise such risks and the proposed studies for learning more about Posaconazole’s risks, are outlined below. Measures to minimise the risks identified for medicinal products can be: Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals; Important advice on the medicine’s packaging; The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly; The medicine’s legal status - the way a medicine is supplied to the patient (e.g.
    [Show full text]
  • Mucormycosis: Botanical Insights Into the Major Causative Agents
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 8 June 2021 doi:10.20944/preprints202106.0218.v1 Mucormycosis: Botanical Insights Into The Major Causative Agents Naser A. Anjum Department of Botany, Aligarh Muslim University, Aligarh-202002 (India). e-mail: [email protected]; [email protected]; [email protected] SCOPUS Author ID: 23097123400 https://www.scopus.com/authid/detail.uri?authorId=23097123400 © 2021 by the author(s). Distributed under a Creative Commons CC BY license. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 8 June 2021 doi:10.20944/preprints202106.0218.v1 Abstract Mucormycosis (previously called zygomycosis or phycomycosis), an aggressive, liFe-threatening infection is further aggravating the human health-impact of the devastating COVID-19 pandemic. Additionally, a great deal of mostly misleading discussion is Focused also on the aggravation of the COVID-19 accrued impacts due to the white and yellow Fungal diseases. In addition to the knowledge of important risk factors, modes of spread, pathogenesis and host deFences, a critical discussion on the botanical insights into the main causative agents of mucormycosis in the current context is very imperative. Given above, in this paper: (i) general background of the mucormycosis and COVID-19 is briefly presented; (ii) overview oF Fungi is presented, the major beneficial and harmFul fungi are highlighted; and also the major ways of Fungal infections such as mycosis, mycotoxicosis, and mycetismus are enlightened; (iii) the major causative agents of mucormycosis
    [Show full text]